Drug intelligence / Profile preview

BHV-1955

Development stage: Preclinical
Lead developer: Biohaven
Modality: Peptides
Administration: Intranasal

Overview

BHV-1955 is a preclinical-stage intranasal formulation of oxytocin being developed by BH Therapeutics, a subsidiary of Biohaven, for the treatment of tinnitus. As an agonist of the oxytocin receptor (OXTR), the drug is designed to modulate oxytocin-mediated neural signaling within the central nervous system. The intranasal route of administration is intended to facilitate direct-to-brain delivery, bypassing the blood-brain barrier to address the underlying neurological components of tinnitus, a condition characterized by persistent phantom auditory perceptions.

Other names: intranasal oxytocin

Targets

AVPR1A (Arginine vasopressin receptor 1A)Oxytocin receptor

Beyond the preview

Go deeper on BHV-1955.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BHV-1955.

Explore the full profile